Zobrazeno 1 - 10
of 16
pro vyhledávání: '"John Curfman"'
Publikováno v:
Biophysical Journal. 111:2551-2561
Determining the pattern of methylation at CpG dinucleotides in a cell remains an essential component of epigenetic profiling. The correlations among methylation, gene expression, and accompanying disease have just begun to be explored. Many experimen
Autor:
James S. Blachly, Mike W. Zoller, Pearlly S. Yan, Ralf Bundschuh, Mark Murphy, Javkhlan-Ochir Ganbat, John C. Byrd, Jincheol Park, Shili Lin, David Frankhouser, John Curfman, Guido Marcucci
Publikováno v:
Bioinformatics. 30:3567-3574
Motivation : DNA methylation is an epigenetic change occurring in genomic CpG sequences that contribute to the regulation of gene transcription both in normal and malignant cells. Next-generation sequencing has been used to characterize DNA methylati
Autor:
Alison Walker, John Curfman, Ann-Kathrin Eisfeld, Samson T. Jacob, Ramasamy Santhanam, Cheryl Kefauver, Susan Geyer, Kenneth K. Chan, Sebastian Schwind, Hongyan Wang, Guido Marcucci, Susan P. Whitman, William Blum, Michael A. Caligiuri, Ramiro Garzon, Celia Garr, Clara D. Bloomfield, Steven M. Devine, Michael R. Grever, Somayeh S. Tarighat, Danilo Perrotti, John C. Byrd, Rebecca B. Klisovic
Publikováno v:
Blood. 119:6025-6031
We recently reported promising clinical activity for a 10-day regimen of decitabine in older AML patients; high miR-29b expression associated with clinical response. Subsequent preclinical studies with bortezomib in AML cells have shown drug-induced
Autor:
Meir Wetzler, John Curfman, Michael A. Caligiuri, Heiko Becker, Sebastian Schwind, Klaus H. Metzeler, Joseph O. Moore, Dean Margeson, Richard A. Larson, Kati Maharry, Susan P. Whitman, Thomas H. Carter, Maria R. Baer, William Blum, Andrew J. Carroll, Yue-Zhong Wu, Jonathan E. Kolitz, Bayard L. Powell, Kelsi B. Holland, Clara D. Bloomfield, Michael D. Radmacher, Krzysztof Mrózek, Guido Marcucci
Publikováno v:
Journal of Clinical Oncology. 29:1373-1381
Purpose To determine the frequency of TET2 mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in patients with primary cytogenetically normal acute myeloi
Autor:
John Curfman, Heiko Becker, Alison Walker, William Blum, Shujun Liu, Cheryl Kefauver, Larry J. Schaaf, Ramiro Garzon, Jon Mickle, Susan P. Whitman, John C. Byrd, Rebecca B. Klisovic, Jason C. Chandler, Steven M. Devine, Guido Marcucci, Mitch A. Phelps, Xiaoxia Yang, Michael R. Grever, Darlene M. Rozewski
Publikováno v:
Journal of Clinical Oncology. 28:4919-4925
Purpose Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia. Patients and Methods Thirty-one adult
Autor:
Hanna S. Radomska, Yue-Zhong Wu, Huating Wang, Flavia Pichiorri, Monica L. Guzman, Houda Alachkar, Guido Marcucci, Jason H. Mendler, Paolo Neviani, Jihane Khalife, Jennifer N. Saultz, John Curfman, Adrienne M. Dorrance, Robert J. Lee, Xiaomeng Huang, Danilo Perrotti, Michael A. Caligiuri, Ly James Lee, Clara D. Bloomfield, Bruno C. Medeiros, Ramiro Garzon, Carlo M. Croce, Mirela Anghelina, Ramasamy Santhanam
High levels of microRNA-155 (miR-155) are associated with poor outcome in acute myeloid leukemia (AML). In AML, miR-155 is regulated by NF-κB, the activity of which is, in part, controlled by the NEDD8-dependent ubiquitin ligases. We demonstrate tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f245ecdce85650274318132813ec5bf1
https://europepmc.org/articles/PMC4868182/
https://europepmc.org/articles/PMC4868182/
Autor:
K. Mrózek, Constance Bär, Christoph Plass, Yue Zhong Wu, Donna Bucci, John C. Byrd, Andrew J. Carroll, Sebastian Schwind, John Curfman, Ann-Kathrin Eisfeld, Jonathan E. Kolitz, Jason H. Mendler, Thomas H. Carter, Kati Maharry, Susan P. Whitman, Ramiro Garzon, Ralf Bundschuh, Richard Stone, Bayard L. Powell, Clara D. Bloomfield, David Frankhouser, Stefano Volinia, Deedra Nicolet, Meir Wetzler, Klaus H. Metzeler, Guido Marcucci, Pearlly S. Yan, Maria R. Baer, Heiko Becker, Michael A. Caligiuri, Jessica Kohlschmidt
Purpose Molecular risk stratification of acute myeloid leukemia (AML) is largely based on genetic markers. However, epigenetic changes, including DNA methylation, deregulate gene expression and may also have prognostic impact. We evaluated the clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e73b57da253e1c20413548ffa2baa8c
http://hdl.handle.net/11392/2356343
http://hdl.handle.net/11392/2356343
Autor:
Michael P. Trimarchi, Ralf Bundschuh, John Curfman, Mark Murphy, Guido Marcucci, Pearlly S. Yan, Benjamin Rodriguez, David Frankhouser
Publikováno v:
BMC Genomics
Background DNA methylation is an important epigenetic mark and dysregulation of DNA methylation is associated with many diseases including cancer. Advances in next-generation sequencing now allow unbiased methylome profiling of entire patient cohorts
Autor:
Guido Marcucci, Sebastian Schwind, Thomas W. Prior, Richard A. Larson, Deedra Nicolet, John Curfman, Yue-Zhong Wu, Peter Paschka, Stefano Volinia, Kati Maharry, Klaus H. Metzeler, Mark J. Pettenati, William Blum, Andrew J. Carroll, Ann-Kathrin Eisfeld, Krzysztof Mrózek, Heiko Becker, Jessica Kohlschmidt, Clara D. Bloomfield, Pia Hoellerbauer, Paola Dal Cin, Colin G. Edwards, Michael A. Caligiuri, Jonathan E. Kolitz
Publikováno v:
Blood. 121(2)
The inv(16)(p13q22)/t(16;16)(p13;q22) in acute myeloid leukemia results in multiple CBFB-MYH11 fusion transcripts, with type A being most frequent. The biologic and prognostic implications of different fusions are unclear. We analyzed CBFB-MYH11 fusi
Autor:
Rebecca B. Klisovic, Hok Hei Tam, John Curfman, Michael R. Grever, Klaus H. Metzeler, Pearlly S. Yan, Susan P. Whitman, Ramiro Garzon, Alison Walker, Susan Geyer, Guido Marcucci, William Blum, Mark W. Murphy, Yue Zhong Wu, John C. Byrd, Benjamin Rodriguez, Michael P. Trimarchi, Michael A. Caligiuri, Ralf Bundschuh, Clara D. Bloomfield, Samson T. Jacob, David Frankhouser
Publikováno v:
Blood. 120(12)
The outcome of older (≥ 60 years) acute myeloid leukemia (AML) patients is poor, and novel treatments are needed. In a phase 2 trial for older AML patients, low-dose (20 mg/m2 per day for 10 days) decitabine, a DNA hypomethylating azanucleoside, pr